Systemic and Lower Respiratory Tract Immunity to SARS-CoV-2 Omicron and Variants in Pediatric Severe COVID-19 and Mis-C

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Tang, Juanjie
    • Other Affiliation: Food and Drug Administration
  • Randolph, Adrienne G.
    • Other Affiliation: Harvard Medical School
  • Novak, Tanya
    • Other Affiliation: Harvard Medical School
  • Walker, Tracie C.
    • Affiliation: School of Medicine, Department of Pediatrics
  • Loftis, Laura L.
    • Other Affiliation: Baylor College of Medicine
  • Zinter, Matt S.
    • Other Affiliation: University of California, San Francisco
  • Irby, Katherine
    • Other Affiliation: Arkansas Children's Hospital
  • Khurana, Surender
    • Other Affiliation: Food and Drug Administration
Abstract
  • Mucosal immunity plays an important role in the control of viral respiratory infections like SARS-CoV-2. While systemic immune responses against the SARS-2-CoV-2 have been studied in children, there is no information on mucosal antibody response, especially in the lower respiratory tract of children coronavirus disease 2019 (COVID-19) and post-infectious multisystem inflammatory syndrome in children (MIS-C) against emerging SARS-CoV-2 variants. Therefore, we evaluated neutralizing antibody responses in paired plasma and endotracheal aspirates of pediatric severe, acute COVID-19 or MIS-C patients against SARS-CoV-2 WA1/2020, as well as against variants of concern (VOCs). Neutralizing antibody responses against the SARS-CoV-2 WA1/2020 strain in pediatric plasma were 2-fold or 35-fold higher compared with the matched endotracheal aspirate in COVID-19 or MIS-C patients, respectively. In contrast to plasma, neutralizing antibody responses against the VOCs and variants of interest (VOIs) in endotracheal aspirates were lower, with only one endotracheal aspirate demonstrating neutralizing titers against the Iota, Kappa, Beta, Gamma, and Omicron variants. In conclusion, our findings suggest that children and adolescents with severe COVID-19 or MIS-C have weak mucosal neutralizing antibodies in the trachea against circulating SARS-CoV-2 Omicron and other VOCs, which may have implications for recovery and for re-infection with emerging SARS-CoV-2 variants.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 3.0 United States
Journal title
  • Vaccines
Journal volume
  • 10
Journal issue
  • 2
Page start
  • 270
Language
  • English
Version
  • Publisher
ISSN
  • 2076-393X

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details vaccines-10-00270.pdf 2022-03-29 Public Download